Institution
West Virginia University
Education•Morgantown, West Virginia, United States•
About: West Virginia University is a education organization based out in Morgantown, West Virginia, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 25632 authors who have published 48308 publications receiving 1343934 citations. The organization is also known as: WVU & West Virginia University, WVU.
Topics: Population, Poison control, Medicine, Pulsar, Health care
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Exposure to iron nanoparticles induces an increase in endothelial cell permeability through ROS oxidative stress-modulated microtubule remodeling, which provides new understandings on the effects of nanoparticles on vascular transport of macromolecules and drugs.
Abstract: Engineered iron nanoparticles are being explored for the development of biomedical applications and many other industry purposes. However, to date little is known concerning the precise mechanisms of translocation of iron nanoparticles into targeted tissues and organs from blood circulation, as well as the underlying implications of potential harmful health effects in human. The confocal microscopy imaging analysis demonstrates that exposure to engineered iron nanoparticles induces an increase in cell permeability in human microvascular endothelial cells. Our studies further reveal iron nanoparticles enhance the permeability through the production of reactive oxygen species (ROS) and the stabilization of microtubules. We also showed Akt/GSK-3β signaling pathways are involved in iron nanoparticle-induced cell permeability. The inhibition of ROS demonstrate ROS play a major role in regulating Akt/GSK-3β – mediated cell permeability upon iron nanoparticle exposure. These results provide new insights into the bioreactivity of engineered iron nanoparticles which can inform potential applications in medical imaging or drug delivery. Our results indicate that exposure to iron nanoparticles induces an increase in endothelial cell permeability through ROS oxidative stress-modulated microtubule remodeling. The findings from this study provide new understandings on the effects of nanoparticles on vascular transport of macromolecules and drugs.
430 citations
••
TL;DR: The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL and supported the approval of romidepsypsin for CTCL.
430 citations
••
TL;DR: In this paper, the authors exploit both plasmon-induced resonant energy transfer and surface Plasmon polaritons in a hematite-gold nano-array, leading to a tenfold increase in the photocurrent at a bias of 0.23
Abstract: Plasmonic nanostructures may enhance solar energy collection. Here, the authors exploit both plasmon-induced resonant energy transfer and surface plasmon polaritons in a hematite–gold nano-array, leading to a tenfold increase in the photocurrent at a bias of 0.23 V in a photoelectrochemical cell.
429 citations
•
TL;DR: The evidence for the effectiveness of long-term opioids in reducing pain and improving functional status for 6 months or longer is variable and the recommendation is 2A - weak recommendation, high-quality evidence: with benefits closely balanced with risks and burdens.
Abstract: BACKGROUND
Opioid abuse has continued to increase at an alarming rate since our last opioid guidelines were published in 2005. Available evidence suggests a continued wide variance in the use of opioids, as documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration.
OBJECTIVES
The objectives of opioid guidelines by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to bring consistency in opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion.
DESIGN
A broadly based policy committee of recognized experts in the field evaluated the available literature regarding opioid use in managing chronic non-cancer pain. This resulted in the formulation of the review and update of the guidelines published in 2006, a series of potential evidence linkages representing conclusions, followed by statements regarding the relationships between clinical interventions and outcomes.
METHODS
The elements of the guideline preparation process included literature searches, literature synthesis, consensus evaluation, open forum presentations, formal endorsement by the Board of Directors of the American Society of Interventional Pain Physicians, and peer review. Based on the criteria of the U.S. Preventive Services Task Force, the quality of evidence was designated as Level I, II, and III, with 3 subcategories in Level II, with Level I described as strong and Level III as indeterminate. The recommendations were provided from 1A to 2C, varying from strong recommendation with high quality evidence to weak recommendation with low-quality or very low-quality evidence.
RESULTS
After an extensive review and analysis of the literature, which included systematic reviews and all of the available literature, the evidence for the effectiveness of long-term opioids in reducing pain and improving functional status for 6 months or longer is variable. The evidence for transdermal fentanyl and sustained-release morphine is Level II-2, whereas for oxycodone the level of evidence is II-3, and the evidence for hydrocodone and methadone is Level III. There is also significant evidence of misuse and abuse of opioids. The recommendation is 2A - weak recommendation, high-quality evidence: with benefits closely balanced with risks and burdens; with evidence derived from RCTs without important limitations or overwhelming evidence from observational studies, with the implication that with a weak recommendation, best action may differ depending on circumstances or patients' or societal values.
CONCLUSION
Opioids are commonly prescribed for chronic non-cancer pain and may be effective for short-term pain relief. However, long-term effectiveness of 6 months or longer is variable with evidence ranging from moderate for transdermal fentanyl and sustained-release morphine with a Level II-2, to limited for oxycodone with a Level II-3, and indeterminate for hydrocodone and methadone with a Level III. These guidelines included the evaluation of the evidence for the use of opioids in the management of chronic non-cancer pain and the recommendations for that management. These guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Because of the changing body of evidence, this document is not intended to be a \"standard of care.\
428 citations
••
TL;DR: In this paper, the authors use the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to improve and expand the quantification of personal health-care access and quality for 195 countries and territories from 1990 to 2015.
427 citations
Authors
Showing all 25957 results
Name | H-index | Papers | Citations |
---|---|---|---|
Graham A. Colditz | 261 | 1542 | 256034 |
Zhong Lin Wang | 245 | 2529 | 259003 |
Michael Kramer | 167 | 1713 | 127224 |
Gabriel Núñez | 148 | 466 | 105724 |
Darwin J. Prockop | 128 | 576 | 87066 |
Adrian Bauman | 127 | 1061 | 91151 |
Chao Zhang | 127 | 3119 | 84711 |
Robert J. Motzer | 121 | 883 | 80129 |
Mark W. Dewhirst | 116 | 797 | 57525 |
Alessandra Romero | 115 | 1143 | 69571 |
Xiaoming Li | 113 | 1932 | 72445 |
Stephen M. Davis | 109 | 675 | 53144 |
Alan Campbell | 109 | 687 | 53463 |
Steven C. Hayes | 106 | 450 | 51556 |
I. A. Bilenko | 105 | 393 | 68801 |